Rani Therapeutics Holdings, Inc. (RANI): Capital Expenditures
$88.0K
Year ended 2025-12-31
$47.0K
Trailing 12 months to 2026-06-30
-62.1%
3-year compound annual growth
-40.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $88.0K | -67.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $268.0K | -78.2% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $1.23M | -24.1% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.62M | +220.0% | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | $506.0K | -57.8% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $1.20M | n/a | 2022-03-31, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $88.0K | -67.2% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2024-12-31 | $0 | -100.0% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.50M | +48.3% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $5.5K | n/a |
| Lipocine Inc. (LPCN) | 2024-12-31 | $90.1K | +584.2% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $112.0K | -18.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $245.0K | -62.6% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $2.0K | -71.4% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $600.0K | n/a |
Compare RANI, NRXP, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗